Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Background First-line imatinib treatment can be successfully discontinued in patients with
chronic myeloid leukaemia after deep molecular response has been sustained for at least 2 …

Purpose To review and update the European LeukemiaNet (ELN) recommendations for the
management of chronic myeloid leukemia with imatinib and second-generation tyrosine …

Abstract Mutations in the Bcr-Abl kinase domain may cause, or contribute to, resistance to
tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia patients. Recommendations …

Purpose Bosutinib is an oral Src/Abl tyrosine kinase inhibitor. The phase III Bosutinib
Efficacy and Safety in Newly Diagnosed Chronic Myeloid Leukemia (BELA) trial compared …

Efforts to discover new cancer drugs and predict their clinical activity are limited by the fact
that laboratory models to test drug efficacy do not faithfully recapitulate this complex disease …

Abstract Bosutinib, a dual Src/Abl kinase inhibitor, has shown potent activity against chronic
myeloid leukemia (CML). In this phase 1/2 study we evaluated bosutinib in patients with …

The success of tyrosine kinase inhibitors (TKIs) in select patients with non–small-cell lung
cancer (NSCLC) has transformed management of the disease, placing new emphasis on …

Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer
research and therapy. These range from the identification of the first specific chromosomal …